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THE work reported here was conducted primarily to assess the behaviour of
a colloidal radioactive chromic phosphate, Cr32PO4 injected into serous cavities
which contain effusions resulting from neo-plastic processes. This followed a
request by the Standing Committee on Radio-Isotopes of the National Health
and Medical Research Council (Australia) to investigate the safety and usefulness
of the colloidal Cr32PO4 prepared by the Radio-chemical Centre, Amersham,
England, since, as far as was known, this particular preparation had not been
used clinically before for this purpose. There had been several favourable reports,
however, on the use of colloidal Cr32PO4 produced by American laboratories,
(Root et al., 1954; Jaffe, 1955).
The present studies provide only preliminary results as to the efficacy of
colloidal Cr32PO4 in the treatment of malignant effusions. Clinical material
was accepted as it became available and as supplies of the colloidal Cr32PO4 were
received in this country from Amersham, and careful physical and clinical studies
were carried out in each case.
Hitherto in Australia certain malignant serous effusions have been treated
in a number of centres with radio-active colloidal gold (198Au) but the quantities
used, 100-150 millicuries, create problems in the protection of the staff handling
the material and nursing the patient. The substitution of colloidal Cr32PO4 for
colloidal 198Au is considered particularly desirable since 32p is a pure beta emitter
and the radiation hazard to personnel can be reduced considerably. Furthermore
32p has a longer half life than 198Au and its beta radiation is more energetic and
therefore more penetrating. Consideration of these physical properties means
that, provided the material is not lost from the cavity, 10 mc. Cr32PO4 will deliver
approximately the same amount of radiation to the serous wall as 100 mc. 198Au.
In studies of this nature the fundamental problem always arises as to the
rationale ofthe treatment in question but a considerable ignorance exists regarding
the underlying mechanisms of effusions in malignant disease.
The accumulation of fluid in serous cavities may be analysed in terms of a
three-compartment model consisting of a vascular bed, serous cavity and
lymphatics; and transfer of fluid normally takes place between these compart-
ments as a dynamic process with the result that in health a minimum of free
fluid accumulates in the cavity. Prentice, Siri and Joiner (1952) in studies using
water labelled with tritium have shown that a large turnover of peritoneal fluid
takes place in patients with ascites. They found that in the presence of 6 litres
of ascitic fluid the daily turnover was between 58 and 115 litres. With such a182 VAN DEN BRENK, CLARKE, HOLMAN AND CARMYL WINKLER
large turnover only a slight interference with either production or absorption
could lead to a large accumulation of fluid.
Straube (1958) in a very carefully planned series of investigations using
Ehrlich's ascites tumour in mice has studied the accumulation of fluid during the
initial stages of tumour growth, particularly the part played by the presence of
malignant cells and possible mechanisms for lymphatic blockage. Whilst neither
increase of vascular permeability nor interference with lymphatic drainage and
permeability can account entirely for the change observed they can be implicated,
particularly the latter.
Adding to confusion are the frequent pathological findings that (1) an intract-
able effusion in a patient with malignant disease often contains few or no free
malignant cells, (2) the effusion may be clear or blood stained, and (3) the associ-
ated serosal surface frequently shows minimal signs of malignant ulceration or
infiltration. Interpretation of clinical results in such circumstances is extremely
difficult and accordingly certain parallel animal experiments were carried out
using a controlled malignant ascitic effusion in mice, caused by Ehrlich's trans-
plantable ascites tumour, for which much quantitative information is available.
The study of these effusions in mice has the advantage that a direct correlation
exists between the accumulation of a protein containing ascitic fluid and the free
ascites tumour cell population. It also affords a quantitative study of the earliest
collection ofthis fluid and the effect of agents on the parameters of cellular popu-
lation and total ascitic volume.
MATERIALS AND METHODS
Radioactive material used
Colloidal Cr32PO4 has been made available from the Radiochemical Centre,
Amersham, at monthly intervals. It is a colloidal suspension prepared by grinding
ignited chromic phosphate in water. The product is centrifuged to remove large
particles and is dialysed to remove ionic material before despatch. No stabilizing
agent is used. The particle size is given as approximately 005 It with aggregates
up to 0-3 #. (Charlton, 1958, personal communication).
The first consignment received was one of 5 mc., thereafter consignments were
of the order of 12 mc. It was not always possible to use the material as soon as
it arrived because suitable patients were not always available, and in addition
to loss by decay doses were further reduced by the aliquots taken for various
physical studies. The whole of the remainder of the consignment of Cr32PO4
was administered to the patient in each case and the doses ranged from 4.8 mc.
to 12.9 mc.
Clinical material
Ideally the natural history of the individual's disease should be relatively
benign, the history (particularly of the serous effusion) should be long and there
should be no severe symptoms which are not referable to the presence of the
fluid. Cases at a terminal stage with malnutrition and anaemia are unsuitable,
and another contra-indication in the case of ascites is the presence of palpable
masses in the abdomen and any other evidence ofthe probability ofgross adhesions
causing loculation. This selection of patients has been easier to describe than to
perform and because the colloidal Cr32PO4 has been received only at regularRADIOACTIVE CHROMIC PHOSPHATE IN EFFUSIONS
intervals it has not been possible on all occasions to insist on the above clinical
indications.
This series of cases included 9 with pleural effusion and 7 with peritoneal
effusion caused by a variety ofprimary tumours as detailed in Table I.
CLINICAL METHOD
On receipt of each consignment of Cr32PO4 an aliquot of the solution was
diluted in distilled water and dialysed for 24 hours using Nojax casing (a cellulose
casing containing glycerine, water and a little sulphur) which has a permeability
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FIG. 1.-Technique for the intracavity administration of Cr32PO4 (see text).
ofapproximately 2-4 mpu. The solution was then autoclaved ready for administra-
tion to the patient. In the last case reported here (J. B-) the whole dose was
dialysed for 24 hours and the quantity remaining in the sac after this period
was then autoclaved for administration. Occasionally the solution flocculated
but while this was undesirable it was not considered a contra-indication to its
use. It could be resuspended by shaking after which it settled out slowly.
Administration was carried out as follows (Fig. 1). Sufficient fluid was with-
drawn from the serous cavity so that as far as could be foreseen no further para-
centesis would be necessary for at least five or six days; this allowed time for
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the Cr32PO4 administered into the cavity to plate out on to the serous wall. It
was the practice not to attempt to drain the cavity but to leave 2 or 3 pints to
ensure that the Cr32P04 was introduced into a reasonable volume thereby improv-
ing the likelihood of a good distribution throughout the cavity.
Following paracentesis the rubber tubing of the canula side arm was clamped
off at A and pierced by the needle B of the 20 ml. syringe assembly. Cr32PO4
was withdrawn from the dose bottle into the 20 ml. syringe and introduced
into the serous cavity via needle B and the canula. Several saline rinses from the
50 ml. syringe were introduced into the dose bottle, withdrawn into the 20 ml.
syringe and introduced into the serous cavity in a similar manner to the dose.
The whole apparatus was thus well rinsed and the dose was given in a total volume
of about 70 ml.
In order to obtain as good a distribution of Cr32PO4 as possible the patient
was required to turn a quarter ofa turn every quarter ofanhourfor the subsequent
two hours, the foot of the bed being raised for the first hour and the head of the
bed for the second hour.
Using a collimated scintillation counter, containing a NaI (T1) crystal, to
detect the 32p bremsstrahlung a radio-active survey of the patient was carried
out about three hours after administration in order to ascertain how well the
32p was distributed throughout the serous cavity, and a similar survey was made
after a few days to check the distribution.
Samples of serous fluid and blood were taken for radioactive assay at two
hours after administration and at other times during the first six or seven days.
Urine was collected in 24 hour samples for several days for radioactive assay.
Peripheral blood cell counts were carried out where possible for several weeks.
Two cases (M.G., a pleural effusion and F.O'D., a peritoneal effusion) came to
autopsy. Samples ofpleura and its underlying muscle, peritoneum and diaphragm
were taken and the surface areas measured. These samples were then digested
in 10 N Nitric Acid and assayed using an M6 liquid counter.
Quantities of 32p have been corrected in all cases to the time ofadministration
of the corresponding dose.
EXPERIMENTAL METHODS
Hybrid Mice of the Walter and Eliza Hall Institute stock weighing 25-30
g. were used throughout in these experiments. The transplantable Ehrlich ascites
tumour used was the hyperdiploid line ELD (Lettre) with a 46 chromosome mode.
The tumour was passaged and maintained in C3H mice in the laboratories of
the Peter MacCallum Clinic.
For a given experiment tumour cells from a single donor mouse were used
to inoculate both control and treated animals. The donor cell population for
inoculation was aspirated and counted in a Neubauer haemocytometer after
dilution in Tyrode solution at 37.5° C. Before counting the sample was further
diluted in a 0.05 per cent solution of eosin (Gurr; Water Soluble Yellowish)
in phosphate buffered saline pH 7.4 (Dulbecco and Vogt, 1954), and a differential
count of viable and non-viable tumour cells was made according to the method
of Hoskins, Meynell and Sanders (1956). Usually an inoculation dose of 2 x 106
tumour cells was used per mouse and given intraperitoneally. The mlice were
weighed daily throughout each experiment and the incidence oflethality recorded.RADIOACTIVE CHROMIC PHOSPHATE IN EFFUSIONS
To observe the effect of various size doses of Cr32PO4 mice were given single
intraperitoneal injections varying from 20Ic. to 80 ,uc. per mouse at 48 hours
after inoculation of the animals with the tumour (Groups II-V). This range of
doses was chosen because an intraperitoneal dose of 20 ,tc. Cr32PO4 in mouse was
considered approximately equivalent to an intraperitoneal dose of 10 mc. Cr32P04
in man, based on estimates ofthe volume ofthe peritoneal cavity in the two cases.
Subsequently the effect of fractionation of Cr32PO4 was studied in mice using
two intraperitoneal injections of 75 ,uc. at 3 and 7 days after inoculation.
In separate groups of control and treated mice, inoculated with tumour cells,
small samples of ascitic fluid were aspirated at chosen times after inoculation and
differential counts made of viable and non-viable cells. Random samples were
also examined for tumour cell morphology using Leishman's stain, and for meta-
phase chromosome abnormalities using Diller's orcein squash technique in hypo-
tonic solution. The abdomens of mice which died were opened, the ascitic fluid
measured and the distribution and extent ofsolid tumour deposits were recorded.
RESULTS
Clinical progress ofpatients
The clinical results in the 16 cases in this study are detailed in Table I. Clinical
relief was marked in 8 patients (7 with pleural and 1 with peritoneal effusion);
some improvement was observed in 3 patients (1 withpleural and 2 with peritoneal
effusion); and no improvement was observed in the other 5 patients (1 with
pleural and 4 with peritoneal effusion.)
In the five cases in which there was no improvement, two hadpalpable abdomi-
nal masses and the other three showed rapid clinical deterioration.
Malignant cells were demonstrated in 13 cases before treatment (8 with pleural
and 5 with peritoneal effusion) and were not found in the remaining 3 cases (1
with pleural and 2 with peritoneal effusion).
No significant blood changes attributable to the treatment were observed.
Dialysis ofCr32PO4
The results ofdialysis tests on 14 consignments ofCr32PO4 aregivenin Table II.
The percentage amount of 32p which dialysed in 24 hours varied considerably
from 4-23 per cent, but most of the results lie between 10-20 per cent. There is
no correlation between the percentage dialysed and the time interval between
despatch and dialysis.
Distribution of 32p in the serous cavity measured by external counter
Although the measurement of bremsstrahlung from the 32p in the serous
cavity is not regarded as quantitative it does indicate the gross distribution ofthe
32p. Fig. 2 shows a good distribution of Cr32PO4 in a peritoneal cavity (Patient
E. V-) and Fig. 3 shows a poor distribution in a peritoneal cavity a few hours
after administration in a patient (M. S-) with abdominal adhesions. In this
latter case the Cr32PO4 showed only moderate dispersion over four days at which
time the second survey was made (Fig. 4). It is interesting to note that in this
case the specific radioactivity of the peritoneal fluid fell from 10.5 fc./ml. to
0.1 uc./ml. during this time.
13
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TABLE I.-Clinical Observations in 16 Patients with
Treated with Cr32PO4
Malignant Serous Effusions
Name Age Sex Diagnosis
E. O'K- 46 M. Pleural
effusion
Ca. lung
M. G- 71 F. Ditto
J. C- 45 M. Pleural
effusion.
Reticulum
cell smrcoma
C. J- 43 F. Pleural
effusion.
Malignant
melanoma
M. F- 63 M. Pleural
effusion.
Ca. bronchus
L. S- 66 F. Pleural
effusion.
Ca. breast
J. S- 66 M. Pleural
effusion.
Primary
unknown
J. L- 65 Ditto
J. B- 70 F. Pleural
effusion.
Ca. Breast
M. O'D- 54 ,, Ascites.
Ca. ovary*
F. O'D- 59 ,, Ascites.
Ca. breast*
E. V- 57 M. Ascites.
Ca. bile
duct
O. W- 61 F. Ascites
Ca. ovary
M. P 57 ,, Ditto
C. 67
M.S- 46
Cytology
Malignant
cells
present
Specific
previous
treatment
Nil
)itto X-ray
therapy to
thorax
,, Ditto
Dosage
of
Cr32PO4
(mc.)
5-2
12-0
4-8
,, 1Nil 11-2
,, X-ray
therapy to
thorax
Oestrogens No
malignant
cells found
Malignant
cells
present
Ditto
,,9
No
malignant
cells found
Malignant Oes
cells
present
No St
malignant re
cells found obs
ja
Malignant
cells
present
Ditto Oi
ec
ti
,,9
Distribu-
tion of
Cr32PO4
in
serous
cavity
Good
Clinical
relief
Marked
Survival
since
onset of
symptoms
as at
31 .xii.58
15 wks.
, ,, 5j mths.
Some 17 mths.
None 12 mths.
9-5
6-6
Nil 12.9
9-7
Oestrogens 10.5
Survival
since
injection
ofCr32PO4
as at
31.xii.58
3 wks.
Died.
2i mths.
Died.
11 mths.
Died.
2i mths.
Died.
Marked 11 mths. 4 mths.
Died.
,, 11 yrs. 5 mths.
.. . , 1 yr. 3j mths.
. .,, 18 mths. 2i mths. ., . ,, 7 mths. 1I mths.
Nil 7 -0 Loculated None
;trogens 8-2 . ..
argical 11.0 Good Marked
3lief of
tructive
undice
Nil 9-0 ,, Some
6phor- 4-6 ,, None
-tomy.
K-ray
ierapy
Nil 6-3 . ..
Nitramin 12-3 Loculated Some
* Abdominal masses present.
Over
2 yrs.
Over
6 mths.
1 2 yrs.
5j mths.
Died.
12 days.
Died.
10 mths.
Died.
5 mths. 4i mths.
Died.
3yrs. 6wks.
Died.
3 mths. 21mths.
Died.
3 mths. 1 mth.
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Three hours after administration when the first survey is carried out most of
the Cr32PO4 is still in the serous fluid, but by the time the second survey is made
muchofithasplated out ontothe walls ofthe serouscavity. AlthoughtheCr32PO4
is differently distributed on these two occasions a comparison of the two surveys
may be made, and in each case it has indicated that most of the 32P has been
retained in the cavity.
FIG. 2.-A radioactive survey showing a good distribution of Cr32PO4 in a peritoneal cavity
(Patient E. V-). Numbers represent relative counting rates.
Urinary excretion of 32p
The 32p contained in the urine of patients given Cr32PO4 has been measured
for four days after administration, and the percentage of the dose excreted in
each case is given in Table II. For all the patients except J. B-, the dose was
not dialysed prior to administration and it was found that between 1-5-5 per cent
of the dose was excreted, the average being approximately 2.5 per cent. For
patient J. B-, the dose was dialysed prior to administration and the amount
excreted was thereby reduced to 0-6 per cent. Dialysis of the urine showed that
all of the 32p was in ionic form.
In order to calculate from these excretion figures what percentage of the
Cr32PO4 dose reached the blood in ionic form, three patients were given a known
187
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SITE
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FiG. 3.-A radioactive survey showing a poor distribution ofCr32PO4 a few hours after admini-
stration, in a patient (M. S-) with abdominal adhesions. Numbers represent relative
counting rates.
UPPER BORDER OF PUBIS
FIG. 4.-A radioactive survey of Patient (M. S-) four days after the one shown in Fig. 3,
showing that the dispersion ofthe Cr32PO4 during this period is limited. Numbers represent
relative counting rates.RADIOACTIVE CHROMIC PHOSPHATE IN EFFUSIONS 189
intravenous dose of Na2H32PO4 and the amount of 32p excreted in the urine in
four days was measured. The results were 13, 16 and 17 per cent with an average
ofapproximately 15 per cent.
Assuming that in both the Cr32PO4 and Na2H32PO4 groups of patients the
32p excreted in 4 days is related to the amount of ionic radiophosphate reaching
the blood then :-
Excretion of 32p
following Na2H32PO4
Dose ofNa2H32PO4
reaching blood (= 100%)
Excretion of 32p
following Cr32PO4
Amount of 32p from the Cr32PO4
dose reaching blood.
Comparison of these excretion data indicates that when the Cr32PO4 is not
dialysed prior to administration then approximately 16 per cent of the 32p con-
tained in the dose reaches the blood in ionic form in a very short time. This
figure agrees very well with the average of 15 per cent ofthe dose found to dialyse.
When the Cr32PO4 is dialysed prior to administration the excretion figures
indicate that only about 4 per cent of the 32p reaches the blood.
TABLE II.-Results of Dialysis of Cr32PO4, and the 32p content of Serous Fluid,
Urine and Bloodfollowing the intracavitary Administration ofCr32PO4
Percentage
of Cr32PO4
dialysing
in
24 hours
Patient (%)
Pleural effusions-
E. O'K-.
M. G- .
J.C- -
C. J-
M.F- . 12
L.S- 15
J.S- 12
J.L- . -
J. B-* . 13
Peritoneal effusions-
M. O'D-. -
F. O'D-
E. V-
O. W-
M. P-
C. S-
M. S-
10
4
12
12
21
16
Amount of
Cr32PO4
administered
(mc.)
5.2
12-0
4-8
11-2
9.5 · 6'6
12-9
9- 7
10 97 10.5
7 0
8-2
11 0
9.0
4.6
6-3
12-3
Concentration of 32p in
serous fluid
in pc./ml.10 mc. dose at
2hours 3-5 days Later
7.8
6-0
3.7
14-2
7.7
33-6
19.1
3.5
3-2
0-3
0.4
0-3
0-2
2-4
8-9
8-4
1.0
0-1
3'0
(loculated)
4-2 0-1
3-6 0-1
1-3 0-6
2-9 0-3
1-2 <0-1
10-5 <0-1
(loculated)
0-1 atday29
<0.1 ,, ,, 14
1-8 ,, ,, 7
6-4 ,, , 6
0-1
0-1
0-2
0-06
11
6
6
8
Percentage
of dose
excreted
in
urine in
4 days
2*1
5.0
2*3
2-3
2-7
2-6
3-.7
0-6* .
Amount of 32p
in blood
. .A
During
1st week
(% of Later
dose) (% of dose)
1
1 5-2
1
1-1.5
1
1-1.5
0.5-1
1.5
0.2*
1 at day 13
1 ,, ,, 14
1 ,, ,, 7
0 5 ,, ,, 26
2-2 . 2-5-3.5
2-0
3.0
1-6
2-0
2-2
3-7
1-5
1
1-5-2-5
1
1-5
1-1-5
0-7 . ..
Other consignments of Cr32PO4-
18 -
23 . -
20 .
14
* Whole dose dialysed prior to administration.
6
9 9 9 9
9 9 9 .
9 9 9 9
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Specific concentration of32p in serousfluid
The specific concentrations of 32p in the serous fluid at 2 hours, 3-5 days and
at longer intervals after administration of the Cr32PO4 are given in Table II in
terms of,tc./ml./10 mc. dose. In most cases the specific radioactivity fell to less
than 10percentbythefourthday, achangewhichis much toogreat to be explained
by any increase in volume of the serous fluid.
In four patients (M. F-, O. W-, L. S-, J. S-) the fall in specific radio-
activity was much less marked and the reason for this variation is not understood.
The specific radioactivity of the serous fluid was generally much lower for
peritoneal effusions than for pleural effusions.
32p in blood
The amount of 32p circulating in the blood remained reasonably constant
over the usual period of study of one week and showed only a slight fall in later
samples taken as long as 26 days after administration ofthe Cr32PO4. The results
are given in Table II. In patient J. B-, where dialysis of the Cr32P04 dose was
carried out prior to administration the concentration of 32p in the blood was
appreciably reduced.
The proportion of the circulating 32p incorporated in the red cells builds up
to 70-85 per cent over the first few hours after intracavity administration of
Cr32PO4, after which it remained fairly constant for as long as measurements
were made. The same pattern was followed after intravenous injection of
Na2H32P04.
Distribution ofCr32PO4. At autopsy
The radioactive concentration (Cr32PO4) of various samples of pleura or
peritoneum from the two cases which came to autopsy are given in Table III
in terms of 4ac./sq.cm. per 10 mc. dose.
The striking feature of these results is the very wide variation of the order
of 100: 1. In case M. G-, it could be argued that the Cr32PO4 may have settled
TABLE III.-Distribution ofCr32PO4 over the Serous Wall in Two Cases at Autopsy
(Corrected to the time of administration)
Patient M. G- Patient F. O'D-
Died 21 months after Cr2P04 Died 12 days after Cr92PO
Pleural effusion Peritoneal effusion
uc./sq. cm. yc./sq. cm.
per per
10 mc. 10 mc.
dose dose
Pleura, upper lobe . . . 0 13 Left post peritoneum . 038
Pleura (tumour) upper lobe . . 012 Right post peritoneum . . 0.09
Parietal pleura (superior) . . 0-17 Centre post peritoneum. 0-06
Parietal pleura (tumour) (inferior) . 043 Right lat. peritoneum . . 11
Parietal pleura (inferior) . . 2-3 Left ant. peritoneum 0-2
Diaphragm . . . . . 17-0 Right ant. peritoneum . . . 0-5
Left diaphragm peritoneum . . 0 03
Right diaphragm .. 1*4
Peritoneum over spleen. . 0.1
Wall of transverse colon . 36RADIOACTIVE CHROMIC PHOSPHATE IN EFFUSIONS
under gravity to the lower regions ofthe pleural cavity, but there is no apparent
pattern in the results of Case F. O'D-.
In Case M. G-, assay of the muscle underlying the pleura indicated a very
marked fall off in radioactivity within a millimetre of the pleural surface.
Results on experimental animals
Survival studies.-All inoculated animals in both control and treated groups
died. The mean survival for various groups is recorded in Table IV.
Single injections of Cr32PO4 in doses from 20 ,c.-80 pc. per mouse failed to
influence significantly the lethality from Ehrlich ascites tumour. When the dose
was repeated (Group IX) and 75,tc. given on the third and seventh days oftumour
ce 0
Lei
I.
C
TIME, DAYS
FIG. 5.-Survival curves for control inoculated mice injected with saline and inoculated mice
receiving 2 doses of 75 pc. Cr32PO4 intraperitoneally, on 3rd and 7th day after inoculation,
respectively (see text).
growth, the survival curve showed a biphasic trend, and nearly 50 per cent of
animals died rapidly. apparently the result of the effects of total body irradiation
(Fig. 5).
Accumulation of Ascites Fluid.-Colloidal Cr32PO4 in doses of 20-80 ,c. given
on the second day after inoculation caused a decrease in the usual gain it animal
weight recorded over the first twelve days after inoculation with the tumour
(Table IV, Groups II-V). Asimilarstriking result was seen after theadministration
oftwo doses of 75,uc. on the third and seventh days oftumour growth (Group X).
This alteration in weight increase was due to a diminution in the accumulation
of ascitic fluid. Measurements of daily fluid intake of treated and control mice
revealed no essential difference in the daily consumption. For treated animal
groups the mean daily fluid consumption per mouse for the first seven days after
injection of Cr32PO4 ranged from 4-5 ml. to 6.9 ml., whilst control animals gave
a corresponding range of 4.6 to 5.9 ml. This finding differs from that observed
by van den Brenk and Parsons (1958) in the treatment of tumour inoculated
mice with orally administered hydrogen peroxide, where the reduction in ascitic
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TABLE IV.-Effect of Colloidal Cr32PO4 Administered Intraperitoneally to Hybrid
Walter and Eliza Hall Mice at Various Times after Inoculation with 2 x 106
cells of Ehrlich ascites Tumour
Weight
Mean increase
animal or loss
weight on Mean survival over first
Number day of time 12 days after
of inoculation A_ inoculation
Group animals (g.) (i SD) (Days) (g.)
I. Control (for Groups II-V) 9 . 42'8 . 166 (±2-1) +8-5
II. 20 Mc. at 48 hours . . 9 . 46-0 . 158 (±1-9) + 1.
III. 40 Mc. at 48 hours . 10 . 43-1 . 17.6, (±3- 1) +0.1I
IV. 60 1c. at 48 hours . 10 . 46-5 . 17-4 (±3.0) . -1.0
V. 80 pc.at48hours . 10 . 41-5 . 19-0 (±62) -3-8
VI. Controls (for Groups VII 10 . 28-1 . 18-6 (± ) 1-3)
and VIII)
VII. 20 Mc. at 24 hours . . 10 . 28-5 . 18-0 (±1-5) .
VIII. 20 pc. at 8 days . . 10 . 29-0 . 16-6 (±2-.5)
IX. Control (for Group X) . 20 36- 6 . 17-0 (±36) . +13*1
X. 2 x 75pc.at3and7days 19 . 37-1 15-3 (±5-6) 7. -75
distension and body weight corresponded to reduced fluid intake and general
dehydration of the treated animals.
Post-mortem examinations ofCr32PO4 treated mice showed a marked reduction
ofasciticfluid, butlarge massesoftumourwereadherenttomesenteriesandabdomi-
nal viscera. The measurement of residual ascitic fluid post-mortem was an
unsatisfactory determination owing to the interval which elapsed between death
and the examination. Similarly the measurement of the ascitic fluid volume
in vivo using dye dilution techniques was very unsatisfactory owing to turbidity
ofthe fluids, the high contamination ofthe fluid with blood cells in many animals,
and loculation offluid in the treated mice in particular.
Tumour cell population.-Repeated measurements of the cell population in
separate groups of control and treated animals showed a relative reduction in
the number of tumour cells per unit volume ascitic fluid in the Cr32PO4 treated
animals (Fig. 6). This reduction was particularly marked on the fourth day after
administration of the Cr32PO4. Thereafter the tumour cell counts in all groups
continued to fall, approaching a similar low level which was maintained until
death of the animals.
Differential counts of non-viable cells, using the eosin technique, were made
and in the control animals a sharp rise in the non-viable count occurred in the
days immediately preceding death of the animals. The non-viable count was not
raised in the isotope treated animals nor did it show the sharp rise before death
recorded in control mice; it would appear that the effect of the irradiation is
to inhibit cellular proliferation.
DISCUSSION
In most of the 16 cases studied the fall in the specific radioactivity of the
serous fluid is far too great to be explained by an increase in its volume, a feature
which has been observed by others (Root et al., 1954), and since the body surveys
indicate that most of the 32p remains in the serous cavity it must be concludedRADIOACTIVE CHROMIC PHOSPHATE IN EFFUSIONS
that the Cr32PO4 plates out on to the serous wall. The rate at which this plating
out process takes place varies considerably but in most cases it is nearly complete
after a few days. The concentration ofthis 32p over the serous wall however, has
been shown from samples taken at two autopsies to vary very widely by a factor
of 100 and determination ofthe dose ofCr32PO4 to be administered must therefore
be empirical.
In this series no difference in dose has been made to allow for the smaller area
of pleural cavities compared with peritoneal cavities, as suggested by Lange,
Shields and Rozendaal (1956), or to allow for the various types ofprimary tumour.
The size of the doses used for patients (Table I) shows no relation to the clinical
results which followed. On the other hand, in the animal experiments where
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FIG. 6.-Progressive tumour cell counts in ascitic fluid at various times after inoculation ofmice
with 2 X 106 cells Ehrlich ascites tumour, in control animals and animals treated with
single intraperitoneal injections ofCr32PO4 48 hours after inoculation.
conditions were better controlled a definite relationship was observed between
dose and both fluid formation and cell counts.
Instability of a Cr32PO4 preparation not only reduces its efficacy as a source
of local radiation of a serous cavity but may produce an unacceptable amount
of 32p in ionic form with rapid access to bone marrow.
On receipt of the Cr32PO4 about 15 per cent of the 32p is found to be in ionic
form and, as the material is dialysed prior to despatch from Amersham, this
quantity must dissociate during the flight of approximately five days between
England and Australia. The doses of Cr32PO4 used have been of the order of
10 mc. so the amount of ionic radioactive phosphate present amounts to about
1 mc. This is an undesirable feature and one that can be largely removed by
dialysis of the material just prior to administration, but iffacilities are not avail-
able for dialysis the amount of ionic radiophosphate present is not considered
unacceptable for this type ofcase. To what extent furtherionization oftheCr32PO4 continues after absorption of the colloid by the serous wall is not known, but the
hazard of additional radioactive phosphate being absorbed is considered to be
very small.
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In animal experiments, not reported here, the effects of198Au and Nitramin on
fluid formation and cell counts have been shown to be similar to those observed
using Cr32P04. This is consistent with reports of clinical experience with these
agents (e.g. Hilton et al. 1957; Bonte, Storaasli and Weisberger, 1956) and the
8 out of 16 patients in the present series who showed marked clinical improvement
following Cr32PO4 is a comparable result.
CONCLUSION AND SUMMARY
It is considered that the use of radioactive colloidal chromic phosphate, as
prepared by the Radiochemical Centre, Amersham, can be recommended for the
treatment of malignant serous effusions since the hazard to the patient is small,
particularly if the material is dialysed prior to administration. There are no toxic
effects as experienced with cytotoxic drugs, and the hazard to staff handling
the material and nursing the patient is negligible compared with radioactive
colloidal gold.
The radioactive colloidal chromic phosphate was purchased by the National
Welfare Fund of the Commonwealth Department of Health and procured by the
Commonwealth X-ray and Radium Laboratory.
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